Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4083
Abstract: 4083Background: Preclinical models indicate that androgen receptor (AR) interference with ENZA is deleterious to HCC; however, ENZA also activates feedback circuitry that may be overcome with the a... read more here.
Keywords: hcc; study enzalutamide; without sorafenib; enza without ... See more keywords
Results from a phase Ib/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.5054
Abstract: 5054 Background: Preclinical models have shown that autophagy is a cell survival mechanism to overcome treatment-induced stress and facilitate progression and resistance in CRPC. Metformin (met) demonstrates autophagy inhibition and resensitizes CRPC tumors to enzalutamide… read more here.
Keywords: study enzalutamide; crpc; treatment; results phase ... See more keywords